Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) Return on Sales (2021 - 2025)

Historic Return on Sales for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to 0.07%.

  • GeneDx Holdings' Return on Sales rose 400.0% to 0.07% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.01%, marking a year-over-year increase of 3200.0%. This contributed to the annual value of 0.17% for FY2024, which is 7000.0% up from last year.
  • Per GeneDx Holdings' latest filing, its Return on Sales stood at 0.07% for Q3 2025, which was up 400.0% from 0.11% recorded in Q2 2025.
  • GeneDx Holdings' Return on Sales' 5-year high stood at 0.76% during Q3 2021, with a 5-year trough of 5.03% in Q4 2022.
  • Over the past 5 years, GeneDx Holdings' median Return on Sales value was 0.7% (recorded in 2021), while the average stood at 0.95%.
  • Per our database at Business Quant, GeneDx Holdings' Return on Sales crashed by -43400bps in 2022 and then soared by 45800bps in 2023.
  • Quarter analysis of 5 years shows GeneDx Holdings' Return on Sales stood at 0.7% in 2021, then plummeted by -624bps to 5.03% in 2022, then skyrocketed by 91bps to 0.45% in 2023, then surged by 113bps to 0.06% in 2024, then crashed by -215bps to 0.07% in 2025.
  • Its Return on Sales stands at 0.07% for Q3 2025, versus 0.11% for Q2 2025 and 0.07% for Q1 2025.